Lv41
450 积分 2022-01-05 加入
Anti-IL-4/IL-13 for the treatment of asthma: the story so far
4个月前
已完结
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies
5个月前
已完结
Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies
5个月前
已完结
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial
5个月前
已完结
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
5个月前
已完结
Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study
5个月前
已完结
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
5个月前
已完结
Type 2 cytokine signaling in macrophages protects from cellular senescence and organismal aging
9个月前
已完结
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
9个月前
已完结
Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
11个月前
已完结
皖公网安备34019202002308
